non-small cell lung cancer Jan 4, 2023 FDA Approves Foundation Medicine Blood Test as CDx for Rozlytrek Dec 22, 2022 Gilead Sciences, Arcus Biosciences Tout Domvanalimab NSCLC Data as Good News for Anti-TIGIT Approach Premium Dec 21, 2022 Japanese Lung Cancer Genomic Screening Project Expands in Asia-Pacific Dec 19, 2022 AstraZeneca's Imfinzi Fails to Meet Primary Endpoint in PD-L1-high NSCLC Dec 14, 2022 Functional Precision Medicine Firm Kiyatec Raises $18M in Series C Funding Round Dec 13, 2022 FDA Approves Mirati's Krazati for Advanced KRAS-Mutated Lung Cancer Dec 8, 2022 Mirati Therapeutics Sees First-Line Potential in Adagrasib-Keytruda Combo Premium Dec 7, 2022 Dragonfly Therapeutics Begins Phase II Trial of HER2-Targeted NK-Cell Engager Nov 30, 2022 Addario Lung Cancer Medical Institute Begins Study Exploring KRAS Inhibitor Resistance Nov 29, 2022 Alaunos Therapeutics Expecting $15.7M in Common Stock Offering Nov 28, 2022 Studies Assess Tumor Aneuploidy to Guide Immunotherapy Treatment Nov 28, 2022 Exscientia Receives Regulatory Nod to Start AI-Aided Phase I/II Trial Nov 16, 2022 NICE Approves Takeda's Exkivity for EGFR Exon 20 Insertion-Positive NSCLC Nov 11, 2022 J Ints Bio to Begin US Trial of JIN-A02 for EGFR C797S-Mutated NSCLC Nov 10, 2022 Diaceutics, PMC Identify Ways Lung Cancer Patients Are Losing Out on Precision Oncology Therapies Premium Nov 4, 2022 Lumakras Sales More Than Double in Q3 2022 as Amgen's Overall Revenues Decline 1 Percent Premium Nov 1, 2022 Monte Rosa Doses First Patient in Phase I/II Trial of MRT-2359 Oct 26, 2022 Hedera Dx Hopes to Hasten Liquid Biopsy Adoption in Europe With Streamlined Platform Premium Oct 26, 2022 Yale Spinout Modifi Biosciences Nets $2.4M From NCI to Advance Targeted Cancer Drugs Toward Clinic Oct 25, 2022 ImaginAb Doses First Patient in Study of CD8-Targeted PET Imaging Agent in Australia Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer